CN109207424A - A kind of cultural method of immunocyte - Google Patents
- ️Tue Jan 15 2019
CN109207424A - A kind of cultural method of immunocyte - Google Patents
A kind of cultural method of immunocyte Download PDFInfo
-
Publication number
- CN109207424A CN109207424A CN201811245216.9A CN201811245216A CN109207424A CN 109207424 A CN109207424 A CN 109207424A CN 201811245216 A CN201811245216 A CN 201811245216A CN 109207424 A CN109207424 A CN 109207424A Authority
- CN
- China Prior art keywords
- culture
- cell
- immunocyte
- volume
- cultural method Prior art date
- 2018-10-24 Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 26
- 210000004027 cell Anatomy 0.000 claims abstract description 66
- 238000011081 inoculation Methods 0.000 claims abstract description 7
- 239000001963 growth medium Substances 0.000 claims abstract description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims abstract description 3
- 238000004113 cell culture Methods 0.000 claims description 10
- 239000013589 supplement Substances 0.000 claims description 7
- 210000004405 cytokine-induced killer cell Anatomy 0.000 claims description 6
- 238000005406 washing Methods 0.000 claims description 5
- 229920006395 saturated elastomer Polymers 0.000 claims description 4
- 210000000822 natural killer cell Anatomy 0.000 claims description 3
- 230000008676 import Effects 0.000 claims 1
- 235000015097 nutrients Nutrition 0.000 abstract description 17
- 230000003321 amplification Effects 0.000 abstract description 7
- 238000003199 nucleic acid amplification method Methods 0.000 abstract description 7
- 238000011534 incubation Methods 0.000 abstract description 4
- 230000035755 proliferation Effects 0.000 abstract description 3
- 239000000243 solution Substances 0.000 description 46
- 238000005119 centrifugation Methods 0.000 description 26
- 230000000052 comparative effect Effects 0.000 description 12
- 206010028980 Neoplasm Diseases 0.000 description 10
- 230000001133 acceleration Effects 0.000 description 10
- 210000002381 plasma Anatomy 0.000 description 10
- 108010002350 Interleukin-2 Proteins 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 230000004069 differentiation Effects 0.000 description 6
- 239000000835 fiber Substances 0.000 description 6
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000009169 immunotherapy Methods 0.000 description 4
- 210000005259 peripheral blood Anatomy 0.000 description 4
- 239000011886 peripheral blood Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 3
- 229930182566 Gentamicin Natural products 0.000 description 3
- 102000008100 Human Serum Albumin Human genes 0.000 description 3
- 108091006905 Human Serum Albumin Proteins 0.000 description 3
- 210000004748 cultured cell Anatomy 0.000 description 3
- 229960002518 gentamicin Drugs 0.000 description 3
- 230000003340 mental effect Effects 0.000 description 3
- 108010056030 retronectin Proteins 0.000 description 3
- 238000012549 training Methods 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 2
- 229960001008 heparin sodium Drugs 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000036978 cell physiology Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- YRQNKMKHABXEJZ-UVQQGXFZSA-N chembl176323 Chemical compound C1C[C@]2(C)[C@@]3(C)CC(N=C4C[C@]5(C)CCC6[C@]7(C)CC[C@@H]([C@]7(CC[C@]6(C)[C@@]5(C)CC4=N4)C)CCCCCCCC)=C4C[C@]3(C)CCC2[C@]2(C)CC[C@H](CCCCCCCC)[C@]21C YRQNKMKHABXEJZ-UVQQGXFZSA-N 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 238000013456 study Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention discloses a kind of cultural methods of immunocyte, comprising the following steps: (1) acquires peripheral blood mononuclear cells;(2) above-mentioned cell inoculation is cultivated in the culture bottle containing culture medium;(3) cell after above-mentioned steps (2) are cultivated is imported in culture bag, wherein the volume of culture solution is less than the volume of culture bag;(4) immunocyte is harvested.The present invention provides a kind of cultural method of immunocyte, by control incubation in nutrient solution volume and culture bag volume ratio, improve cell amplification ability and finally obtained cell quantity, realize a large amount of proliferation of immunocyte, the utilization rate for improving culture solution, has saved cost.
Description
Technical field
The present invention relates to field of cell culture more particularly to a kind of cultural methods of immunocyte.
Background technique
Currently, malignant tumour is to seriously endanger one of a kind of disease of human health, the main reason for being death, occur With development mainly since human defensive system loses regulation and control to cancer cell, lead to disequilibrium between body and tumour It is caused.Traditional treatment means include operative treatment, radiotherapy and chemotherapy, studies have shown that operation, radiotherapy, chemotherapy energy Curing tumour is not to kill whole tumour cells, but due to when tumor load is substantially reduced, the immune function of body Restore, to remove minimal disease or the obvious proliferation for inhibiting remaining tumor cells.Immunotherapy of tumors is exactly to pass through artificially Intervene, excitation and the immune system for transferring body enhance anti-tumor immunity, thus control and killing tumor cell.
Adoptive immunotherapy (adoptive cellular immunotherapy, ACI) is current more common one Kind immunotherapy of tumors mode is the immune effector cell for having antitumor action by the amplification of external mass propgation, comes direct It kills tumour or excites a kind of therapeutic modality of body anti tumor immune response.Such cell specifically includes that Lymphokine Killing cell (LAK), tumor infiltrating lymphocyte (TIL), cytokine induced kill cell (CIK), natural kill it is thin Born of the same parents (NK) or the T lymphocyte (such as CAR-T, TCR-T) etc. being transformed through gene technology.
For immune cell therapy, sufficient amount of effector cell is the necessary condition for guaranteeing therapeutic effect, therefore is Enough immunocyte quantity is obtained, technical staff just constantly changes the various aspects of production cell by studying and testing Into improving immunocyte quantity by increasing the dosage of culture solution is most simple and effective method, and technical staff is to make to be immunized Cell quantity reaches treatment and requires, and generally can all reach cell culture bags volume to the use volume of culture solution in single culture bag Maximum value or the narrow fluctuation above and below its maximum value, with promotion culture solution dosage as much as possible.Although this method is one Determine to improve cell quantity in degree, but seriously reduces the culture efficiency of culture solution, the immunocyte quantity finally obtained It is extremely limited, it is ineffective.
Summary of the invention
It for overcome the deficiencies in the prior art, can the purpose of the present invention is to provide a kind of cultural method of immunocyte To effectively improve the culture quantity of immunocyte, the utilization rate of culture solution and the culture quantity of cell are substantially increased.
The purpose of the present invention adopts the following technical scheme that realization:
A kind of cultural method of immunocyte, comprising the following steps:
(1) peripheral blood mononuclear cells is acquired;
(2) above-mentioned cell inoculation is cultivated in the culture bottle containing culture medium;
(3) cell after above-mentioned steps (2) are cultivated is imported in culture bag, wherein the volume of culture solution is less than culture The volume of bag;
(4) immunocyte is harvested.
Further, the volume of culture solution and the ratio of culture bag volume are 0.42-0.55:1 in above-mentioned steps (3).
Further, it is put in 37 DEG C after the cell inoculation in above-mentioned steps (2) is in culture bottle, saturated humidity, 5%CO2 It is cultivated 3-5 days in incubator.
Further, in the culture bottle in above-mentioned steps (2) and in the culture solution of step (3) added with cell because Son.
Further, cell is imported into culture bag in above-mentioned steps (3), supplements culture solution, continue to cultivate to after the 2-7 days It expands culture.
Further, the cell culture expanded culture in above-mentioned steps (3) is washed to being centrifuged after the 4-14 days Up to immunocyte after washing.
Further, the immunocyte is one of CIK cell, til cell, NK cell.
Compared with prior art, the beneficial effects of the present invention are: the present invention provides a kind of cultural method of immunocyte, lead to The ratio for crossing nutrient solution volume and culture bag volume in control incubation improves the amplification ability of cell and finally obtained thin Born of the same parents' quantity realizes a large amount of proliferation of immunocyte, improves the utilization rate of culture solution, saved cost.
Detailed description of the invention
Fig. 1 is the cell quantity statistical result datagram of the embodiment of the present invention 1 to 6 and comparative example 1 to 4.
Specific embodiment
In the following, being described further in conjunction with specific embodiment to the present invention, it should be noted that is do not collided Under the premise of, new embodiment can be formed between various embodiments described below or between each technical characteristic in any combination.
1 Fiber differentiation CIK cell of embodiment
(1) it is anticoagulant to extract patient 50ml peripheral blood addition heparin sodium, is sub-packed in two 50ml centrifuge tubes and is centrifuged, from Mental and physical efforts 800G, 4 DEG C, acceleration 9, deceleration 9 is centrifuged 15min, draws upper plasma after centrifugation, be put in 4 DEG C of preservations;By two Haemocyte in centrifuge tube respectively with normal saline dilution to 35ml, slowly filling in equipped with 15ml lymphocyte separation medium from It is centrifuged in heart pipe, 4,20 DEG C of centrifugal force 800G, acceleration 4, deceleration centrifugation 17min, centrifugation terminate, and draw peripheral blood list A nucleus is put in 50ml centrifuge tube, with normal saline dilution to 50ml and is put in centrifuge centrifugation, centrifugal force 300G, acceleration 7, deceleration 5,4 DEG C of centrifugation 8min, wash cell twice;
(2) by the cell inoculation after washing with the pre-coated 75cm for having CD3 monoclonal antibody and RetroNectin of PBS2Culture bottle It is interior, and 30ml GT-T551 culture medium is added, wherein CD3 monoclonal antibody is 15ul/ bottles, RetroNectin is 60ul/ bottles, PBS is 10ml/ bottles, IL-2 1000IU/ml, IFN-r 1000IU/ml, gentamicin 160IU/ml, autologous plasma 5% will Above-mentioned culture bottle is put in 37 DEG C, saturated humidity, 5%CO2It is cultivated 4 days in incubator;
(3) cell is averagely imported in the cell culture bags that two volumes are 1800ml, and supplement is self containing 2% respectively To 75ml, culture expands culture cell to after the 6th day the GT-T551 culture solution that blood plasma and IL-2 are 1000IU/ml, Supplement the volume for the GT-T551 culture solution culture solution into each culture bag for being 1000IU/ml containing 2% autologous plasma and IL-2 For 750ml, the ratio of nutrient solution volume and culture bag volume is 0.42:1, cultivates to after the 12nd day, cultured cell is led Enter Centrifuge Cup to be centrifuged, 5,4 DEG C of centrifugal force 400G, acceleration 7, deceleration centrifugation 8min, be collected after centrifugation immune thin Born of the same parents are in 50ml centrifuge tube and in centrifugal force 300G, acceleration 7,5,4 DEG C of centrifugation 8min of deceleration, and centrifuge washing twice, is added Cell liquid is imported normal saline bag by 2.5% human serum albumin.
2 Fiber differentiation CIK cell of embodiment
The difference of embodiment 2 and embodiment 1 are as follows: nutrient solution volume is 900ml in each culture bag in above-mentioned steps (3), Nutrient solution volume and the ratio of culture bag volume are 0.5:1.
3 Fiber differentiation CIK cell of embodiment
The difference of embodiment 3 and embodiment 1 are as follows: nutrient solution volume is 990ml in each culture bag in above-mentioned steps (3), Nutrient solution volume and the ratio of culture bag volume are 0.55:1.
4 Fiber differentiation CIK cell of embodiment
The difference of embodiment 4 and embodiment 2 are as follows: the culture solution used is ALyS505N, remaining is and embodiment 2 is identical.
5 Fiber differentiation til cell of embodiment
(1) fresh tumor tissue is put in the culture solution containing pake purpke dual anti-and gentamicin and is impregnated 10 minutes, then taken Tumor tissues are put in six orifice plates out, are wiped out fat and necrotic tissue with eye scissors, remaining tumor tissues turn after being cut to fragment Move on to 50ml centrifuge tube, be resuspended with culture solution to being centrifuged after 30 milliliters, centrifugal force 500G, 4 DEG C of centrifugation 5min, remove after centrifugation on Clearly, it is resuspended with culture solution to 10-20ml, and Collagenase I, II, IV (the use of concentration being 0.5mg/ml) is added, centrifuge tube is put into Rotation vortex mixer simultaneously rotates 1-2h, and cell is resuspended to 50ml with physiological saline after rotation, is centrifuged after mixing, centrifugal force 500G, 4 DEG C of centrifugation 5min, remove supernatant after centrifugation, and appropriate physiological saline is added according to cell quantity and mixes, with 100um's Cell strainer filtration cell, is centrifuged again, and centrifugal force 500G, 4 DEG C of centrifugation 5min remove supernatant after centrifugation, by cell physiology Salt water is resuspended to 5ml, and Ficol the and 5ml cell of Ficol, 5ml75% of 5ml100% is sequentially added in the centrifuge tube of 15ml Suspension is then centrifuged for, centrifugal force 800G, and 20 DEG C of centrifugation 17min take out mononuclearcell after centrifugation, is transferred to 15ml centrifugation It manages and is resuspended to 15ml, wash twice, centrifugal force 500G, 40 DEG C of centrifugation 5min;
(2) cell is resuspended in containing in the X-VIVO culture solution that autologous plasma is 2% and IL-2 is 6000IU/ml, is turned 24 orifice plates are moved to, are put in 37 DEG C, saturated humidity cultivates in 5%CO2 incubator, carries out half amount within every 2-3 days in incubation and changes Liquid, cell are transferred to 75cm after reaching certain amount2Culture bottle in cultivated, to be transferred to CD3 mono- after continuing culture 3 days Anti- and RetroNectin pre-coated culture bottle is cultivated, and culture 4 days is continued;
(3) cell is averagely imported in the cell culture bags that two volumes are 1800ml, and supplement contains self blood respectively Slurry is that the X-VIVO culture solution that 2% and IL-2 is 6000IU/ml carries out expansion training to cell after continuing culture 2 days to 90ml It supports, the X-VIVO culture solution that supplement is 2% containing autologous plasma and IL-2 is 6000IU/ml to final volume 900ml, culture solution is whole Volume and the ratio of culture bag volume are 0.5:1, continue culture 4 days, and cultured cell importing Centrifuge Cup is centrifuged, from Mental and physical efforts 400G, 4 DEG C of centrifugation 8min, acceleration 7, deceleration 5, are collected after centrifugation cell in 50ml centrifuge tube and wash twice, add Enter 2.5% human serum albumin, cell liquid is imported into normal saline bag.
6 Fiber differentiation NK cell of embodiment
(1) it is anticoagulant to extract patient 50ml peripheral blood addition heparin sodium, is sub-packed in two 50ml centrifuge tubes and is centrifuged, from Mental and physical efforts 800G, 4 DEG C, acceleration 9, deceleration 9 is centrifuged 15min, draws upper plasma after centrifugation, be put in 4 DEG C of preservations;By two Haemocyte in centrifuge tube respectively with normal saline dilution to 25ml, slowly filling in equipped with 15ml lymphocyte separation medium from It is centrifuged in heart pipe, 4,20 DEG C of centrifugal force 800G, acceleration 4, deceleration centrifugation 17min, centrifugation terminate, and draw peripheral blood list A nucleus is put in 50ml centrifuge tube, with normal saline dilution to 50ml and is put in centrifuge centrifugation, centrifugal force 300G, acceleration 7, deceleration 5,4 DEG C of centrifugation 8min, wash cell twice;
(2) by the cell inoculation after washing in 75cm2In culture bottle, and the GT-T561 culture solution of 40ml is added, wherein certainly Body blood plasma is 5%, IL-2 200IU/mL, IL-15 50ng/mL, IL-21 25ng/mL, gentamicin 160IU/mlL, And the trophocyte (2 × 10 after pipe recovery is added6A K562 cell), in incubation, appropriate supplement contains daily or every other day There is the GT-T561 culture solution that autologous plasma is 2%, IL-2 200IU/mL, IL-15 50ng/mL, IL-21 are 25ngmL, trains It supports to the 5th day and cell is transferred to 175cm2In culture bottle, and fluid infusion is to 150ml, culture to fluid infusion in the 6th day to 300ml;
(3) cell culture was expanded culture to the 7th day, first by the trophocyte cell (5 × 10 after pipe recovery6It is a K562 cell) it is added in culture bottle, cell is averagely imported again after mixing in the cell culture bags that two volumes are 1800ml, and It is supplemented respectively containing the GT- that autologous plasma is 2%, IL-2 200IU/mL, IL-15 50ng/mL, IL-21 are 25ng/mL For T561 culture solution to final volume 800ml, the ratio of culture solution final volume and culture bag volume is 0.44:1;Culture was to the 12nd day Afterwards, cultured cell importing Centrifuge Cup is centrifuged, centrifugal force 400G, 4 DEG C of centrifugation 8min, acceleration 7, deceleration 5, from Cell is collected after the heart in 50ml centrifuge tube and to wash twice, and 2.5% human serum albumin is added, cell liquid is imported into normal saline bag ?.
Comparative example 1
Comparative example 1 provides a kind of cultural method of immunocyte and culture solution of the difference in step (3) of embodiment 1 Total dosage is under conditions of being 1500ml, and the ratio of nutrient solution volume and culture bag volume is 0.83:1, remaining and is implemented Example 1 is identical.
Comparative example 2
Comparative example 2 provides a kind of cultural method of immunocyte and the culture of embodiment 2 being distinguished as in step (3) The total dosage of liquid is under conditions of being 1800ml, and the ratio of nutrient solution volume and culture bag volume is 1:1, remaining is and embodiment 6 is identical.
Comparative example 3
Comparative example 3 provides a kind of cultural method of immunocyte and the culture of embodiment 3 being distinguished as in step (3) The total dosage of liquid is 2000ml, and the ratio of nutrient solution volume and culture bag volume is 1.1:1, remaining is and embodiment 3 is identical.
Comparative example 4
Comparative example 4 provides a kind of cultural method of immunocyte and the culture of embodiment 4 being distinguished as in step (3) The total dosage of liquid is under conditions of being 1800ml, and the ratio of nutrient solution volume and culture bag volume is 1:1, remaining is and embodiment 4 is identical.
The cell amplification ability and cell quantity and embodiment 1 of Statistics Implementation example 1 to 6 and comparative example 1 to 4 respectively To the 4 cell growth rate relative to comparative example 1 to 4, the results are shown in Table 1.
Table 1
Same immunocyte is come it can be seen from the statistical data of embodiment 1 to 6 in upper table 1 and attached drawing 1 It says, in the case where total culture solution dosage is constant, changes the proportionate relationship of nutrient solution volume and culture bag volume, the expansion of cell Energization power and cell quantity can change, although with the reduction of nutrient solution volume and culture bag volume fraction, the expansion of cell Energization power improves, but the dosage due to reducing culture solution in each culture bag, in the case where identical culture solution It needs to be divided in cell in more culture bags, on the one hand increases the triviality of operation, need to take more time, it is another Aspect causes the waste of culture bag, increases cost.Currently preferred nutrient solution volume and the ratio of culture bag volume are 0.42- On the one hand 0.55:1 improves the amplification ability of cell, on the other hand guarantees the efficiency of cell culture, into one in the range Walk save the cost.
Allogenic cell is in the equal situation of culture solution dosage it can be seen from the comparison of embodiment 1 to 4 and comparative example 1 to 4 Under, when nutrient solution volume and culture bag volume are equal or when being slightly larger than culture bag volume, the amplification ability of cell and final Obtained cell quantity is not as good as when nutrient solution volume is less than culture bag volume.Illustrate to show using method provided by the invention Write improve immunocyte amplification ability and finally obtained immunocyte culture quantity, while with the condition of culture of cell, training Environment, cultural method, culture level are supported without direct relation, i.e., experimenter is by improving cell cultivation level or changing cell training Method etc. is supported come after promoting cell quantity, the method that can still provide according to the present invention reasonably selects nutrient solution volume and culture bag The ratio of volume further increases cell quantity.
The above embodiment is only the preferred embodiment of the present invention, and the scope of protection of the present invention is not limited thereto, The variation and replacement for any unsubstantiality that those skilled in the art is done on the basis of the present invention belong to institute of the present invention Claimed range.
Claims (7)
1. a kind of cultural method of immunocyte, which comprises the following steps:
(1) peripheral blood mononuclear cells is acquired;
(2) above-mentioned cell inoculation is cultivated in the culture bottle containing culture medium;
(3) cell after above-mentioned steps (2) are cultivated is imported in culture bag, wherein the volume of culture solution is less than culture bag Volume;
(4) immunocyte is harvested.
2. the cultural method of immunocyte according to claim 1, which is characterized in that the body of culture solution in above-mentioned steps (3) Long-pending and culture bag volume ratio is 0.42-0.55:1.
3. the cultural method of immunocyte according to claim 1, which is characterized in that the cell inoculation in above-mentioned steps (2) It is put in 37 DEG C after in culture bottle, saturated humidity, 5%CO2It is cultivated 3-5 days in incubator.
4. the cultural method of immunocyte according to claim 1, which is characterized in that in the culture bottle in above-mentioned steps (2) And cell factor is added in the culture solution of step (3).
5. the cultural method of immunocyte according to claim 1, which is characterized in that above-mentioned steps import cell in (3) Culture bag supplements culture solution, continues culture to expanding culture after the 2-7 days.
6. the cultural method of immunocyte according to claim 5, which is characterized in that will expand in above-mentioned steps (3) The cell culture of culture is to being centrifuged after the 4-14 days, up to immunocyte after washing.
7. the cultural method of immunocyte according to claim 1, which is characterized in that the immunocyte be CIK cell, One of til cell, NK cell.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811245216.9A CN109207424A (en) | 2018-10-24 | 2018-10-24 | A kind of cultural method of immunocyte |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811245216.9A CN109207424A (en) | 2018-10-24 | 2018-10-24 | A kind of cultural method of immunocyte |
Publications (1)
Publication Number | Publication Date |
---|---|
CN109207424A true CN109207424A (en) | 2019-01-15 |
Family
ID=64996672
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811245216.9A Pending CN109207424A (en) | 2018-10-24 | 2018-10-24 | A kind of cultural method of immunocyte |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109207424A (en) |
Cited By (4)
* Cited by examiner, † Cited by third partyPublication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112251407A (en) * | 2020-11-03 | 2021-01-22 | 广州康琪莱精准医疗科技有限公司 | Amplification culture method of umbilical cord blood CIK cells |
CN114107194A (en) * | 2021-11-22 | 2022-03-01 | 颐华国韵(河南)生物科技有限公司 | Immune cell amplification culture method and device |
WO2022252003A1 (en) * | 2021-05-31 | 2022-12-08 | 北京永泰生物制品有限公司 | Closed culture system |
CN115896016A (en) * | 2022-09-07 | 2023-04-04 | 普华赛尔生物医疗科技有限公司 | Culture composition and application thereof in culturing immune cells |
Citations (7)
* Cited by examiner, † Cited by third partyPublication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102100910A (en) * | 2009-12-21 | 2011-06-22 | 北京清大天一科技有限公司 | Method for producing viral vaccines |
CN102268407A (en) * | 2011-07-20 | 2011-12-07 | 中国科学技术大学 | Large-scale serum-free culture method for rhIL-12 engineering cells |
CN102816735A (en) * | 2012-09-12 | 2012-12-12 | 山东省齐鲁细胞治疗工程技术有限公司 | Method for culturing autologous peripheral blood lymphocytes |
CN105238754A (en) * | 2015-11-20 | 2016-01-13 | 赵顺英 | Method for in vitro culture of high-proliferation and high-mortality NK cells |
CN105505871A (en) * | 2016-02-06 | 2016-04-20 | 福建省银丰干细胞工程有限公司 | Method for effectively amplifying CIK cells and improving specific tumor killing capability of CIK cells |
CN106011061A (en) * | 2016-08-04 | 2016-10-12 | 广东省第二人民医院 | In-vitro large-scale amplification method of natural killer cells |
CN107384860A (en) * | 2017-09-25 | 2017-11-24 | 广州资生生物科技有限公司 | The cultural method of cell culture fluid and NK cells |
-
2018
- 2018-10-24 CN CN201811245216.9A patent/CN109207424A/en active Pending
Patent Citations (7)
* Cited by examiner, † Cited by third partyPublication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102100910A (en) * | 2009-12-21 | 2011-06-22 | 北京清大天一科技有限公司 | Method for producing viral vaccines |
CN102268407A (en) * | 2011-07-20 | 2011-12-07 | 中国科学技术大学 | Large-scale serum-free culture method for rhIL-12 engineering cells |
CN102816735A (en) * | 2012-09-12 | 2012-12-12 | 山东省齐鲁细胞治疗工程技术有限公司 | Method for culturing autologous peripheral blood lymphocytes |
CN105238754A (en) * | 2015-11-20 | 2016-01-13 | 赵顺英 | Method for in vitro culture of high-proliferation and high-mortality NK cells |
CN105505871A (en) * | 2016-02-06 | 2016-04-20 | 福建省银丰干细胞工程有限公司 | Method for effectively amplifying CIK cells and improving specific tumor killing capability of CIK cells |
CN106011061A (en) * | 2016-08-04 | 2016-10-12 | 广东省第二人民医院 | In-vitro large-scale amplification method of natural killer cells |
CN107384860A (en) * | 2017-09-25 | 2017-11-24 | 广州资生生物科技有限公司 | The cultural method of cell culture fluid and NK cells |
Non-Patent Citations (2)
* Cited by examiner, † Cited by third partyTitle |
---|
MINNA M. HANKANIEMI ET AL.: "Optimized production and purification of Coxsackievirus B1 vaccine and its preclinical evaluation in a mouse model", 《VACCINE》 * |
罗渊 等: "一种新型自体NK细胞扩增培养方法的建立和初步临床应用", 《空军医学杂志》 * |
Cited By (6)
* Cited by examiner, † Cited by third partyPublication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112251407A (en) * | 2020-11-03 | 2021-01-22 | 广州康琪莱精准医疗科技有限公司 | Amplification culture method of umbilical cord blood CIK cells |
WO2022252003A1 (en) * | 2021-05-31 | 2022-12-08 | 北京永泰生物制品有限公司 | Closed culture system |
CN114107194A (en) * | 2021-11-22 | 2022-03-01 | 颐华国韵(河南)生物科技有限公司 | Immune cell amplification culture method and device |
CN114107194B (en) * | 2021-11-22 | 2024-01-30 | 颐华国韵(河南)生物科技有限公司 | Immune cell expansion culture method and device |
CN115896016A (en) * | 2022-09-07 | 2023-04-04 | 普华赛尔生物医疗科技有限公司 | Culture composition and application thereof in culturing immune cells |
CN115896016B (en) * | 2022-09-07 | 2023-09-12 | 普华赛尔生物医疗科技有限公司 | Culture composition and application thereof in culturing immune cells |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105238754B (en) | 2016-08-17 | A kind of high proliferation power and the extracorporeal culturing method of High Fragmentation power NK cell |
CN103756963B (en) | 2019-10-29 | A kind of method of amplification in vitro NK cell |
CN109207424A (en) | 2019-01-15 | A kind of cultural method of immunocyte |
CN105087487B (en) | 2018-09-18 | A kind of method of efficient amplification CIK |
CN101519646B (en) | 2011-06-22 | CIK cell, as well as preparation method and cell preparation thereof |
CN103301449B (en) | 2016-01-13 | A kind of preparation method of large-scale culture dendritic cell vaccine and application thereof |
CN103756962A (en) | 2014-04-30 | Method used for in vitro amplification of gamma-delta-T cells |
CN104845934B (en) | 2018-05-11 | Bleeding of the umbilicus CD34+Derived from hematopoietic precursor cells Dendritic Cells is prepared on a large scale method |
CN104593326A (en) | 2015-05-06 | Method for preparing enhanced DC-CIK cell induced by traditional Chinese medicines and application of enhanced DC-CIK cells induced by traditional Chinese medicines |
CN105524880A (en) | 2016-04-27 | Construction method of immune cell bank |
CN105316287A (en) | 2016-02-10 | Method for long-term storage and resuscitation culture of adult peripheral blood mononuclear cell |
CN105925527A (en) | 2016-09-07 | Kit for preparing NK cells and application method thereof |
CN105219713A (en) | 2016-01-06 | For high proliferation power, the High Fragmentation power NK cell of tumour adoptive immunity |
CN107119013A (en) | 2017-09-01 | A kind of preparation method of enhanced CIK cell and the application of soluble polysaccharide and LBP-X |
CN108642013A (en) | 2018-10-12 | From being detached in Cord blood after CD34 candidate stem cells expand culture, induction prepares Dendritic Cells method to one kind on a large scale |
CN105861435A (en) | 2016-08-17 | In-vitro amplification method of natural killer cells (NK) |
CN107502590A (en) | 2017-12-22 | A kind of method of human umbilical cord's blood candidate stem cell efficient amplification NK cells |
CN102676455A (en) | 2012-09-19 | Preparation method for dendritic cell of umbilical cord blood source and dendritic cell vaccine |
CN105505871B (en) | 2019-02-12 | A kind of effective amplification CIK and improve the method that its specificity kills tumor ability |
CN104371973B (en) | 2017-12-05 | A kind of serum free medium of immunocyte |
CN115896016A (en) | 2023-04-04 | Culture composition and application thereof in culturing immune cells |
CN105907714A (en) | 2016-08-31 | Improved method for cultivating NK (natural killer) cells |
CN107384860A (en) | 2017-11-24 | The cultural method of cell culture fluid and NK cells |
CN101914497A (en) | 2010-12-15 | Clinical N-CIK cell culture and quality control and identification kit and application |
CN106047809A (en) | 2016-10-26 | Method for combining with ligand TLR7 to simultaneously amplify human CIK/NK cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
2019-01-15 | PB01 | Publication | |
2019-01-15 | PB01 | Publication | |
2019-02-12 | SE01 | Entry into force of request for substantive examination | |
2019-02-12 | SE01 | Entry into force of request for substantive examination |